Recent studies unveil significant genetic insights shaping diagnosis and therapy. UCLA uncovered a key protein, IGF2BP3, linking cancer metabolism and RNA regulation in leukemia, presenting new therapeutic targets. Precision oncology gains from an immune-based genomic signature predicting CDK4/6 inhibitor response in breast cancer. Other advances highlight mutations involved in vancomycin-resistant Enterococcus and mitochondrial DNA deletions at single-cell resolution. Additionally, multi-omics analyses expose systemic inflammation-gut microbiota interactions in gastric cancer, guiding biomarker-driven approaches.